Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
In conclusion, talquetamab induces deep, durable responses in heavily pretreated myeloma but has unique, mostly manageable toxicities requiring mitigation to sustain therapy. Up-front patient education on expected adverse effects and self-care, close monitoring and early intervention, and prompt dose modifications when needed facilitate tolerance. Skin changes typically resolve with symptomatic relief from barrier creams. Future studies should examine talquetamab in earlier lines to widen accessibility. As experience accrues, best practices for balancing efficacy and quality of life will evolve through ongoing clinician collaboration.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.